Merck/NewLink Ebola vaccine 100% effective in Guinea trial
This article was originally published in Scrip
Executive Summary
Early results of an experimental Ebola vaccine being developed by Merck and its partner NewLink, which licensed the product from the Canadian government, showed the candidate, known as rVSV-ZEBOV, was 100% effective in protecting humans against the virus in a Phase III ring study being conducted in Guinea, researchers reported in the medical journal The Lancet on 31 July.